TheTechno Optimist.

Inspire Medical Systems—Inspire Medical reports Q3 2026 earnings with continued growth in implant volume and insurance coverage expansionInspire Therapy SystemInspire Medical Systems—Inspire V achieves 3.0T MRI compatibility, enabling safer imaging for implanted patientsInspire Therapy SystemInspire Medical Systems—Inspire publishes PREDICTOR study identifying BMI and neck circumference as markers of treatment successInspire Therapy SystemInspire Medical Systems—Inspire reports cardiovascular outcomes: hypoglossal nerve stimulation associated with lower stroke and cardiac event rates than CPAP

Inspire Therapy System

by Inspire Medical SystemsUS

Implantable hypoglossal nerve stimulator for OSA patients intolerant of CPAP. Senses breathing, applies synchronous stimulation. Advances tongue to keep airway open. FDA approved for moderate-severe OSA.

DeployStage 4 of 5

Inspire IV since 2014. Inspire V approved Aug 2024, 3.0T MRI compatible. Rollout ongoing.

Updated May 2026Checked 10 Oct0 updates this week

Milestones

Next · U.S. commercial rollout of Inspire V
  1. Inspire therapy system first approved by FDA2014Complete.
  2. STAR Trial published in NEJM with 68-70% AHI improvement9 Jan 2014Complete.
  3. Medicare Local Coverage Determinations issued for InspireAug 2019Complete.
  4. Two-incision procedure FDA approved, reducing operative timeJan 2021Complete.
  5. Inspire V next-generation system FDA approved2 Aug 2024Complete.
  6. Inspire V achieves 3.0T MRI compatibility2026Complete.
  7. PREDICTOR and cardiovascular studies publishedMay 2026Complete.
  8. U.S. commercial rollout of Inspire VTarget 2026Current milestone.

Most important updates

Upcoming

  1. 2026U.S. commercial rollout of Inspire V (next)
  2. 2027Expansion into international markets beyond Singapore
  3. 2027Long-term cardiovascular outcome trials
Primer